Computational Design and Optimization of Peptide Inhibitors for SIRT2
Pharmaceuticals · 24.08.2024 · 17 (9) · 1120
DOI: 10.3390/ph17091120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 24.08.2024. Verfasst von Heba A Alkhatabi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Abdulaziz University, The Deanship of Scientific Research (DSR) at King Abdulaziz University (KAU), Jeddah, Saudi Arabia.
Abstract (Originalsprache)
Sirtuin 2 (SIRT2), an NAD+-dependent deacetylase, is crucial for regulating vital physiological processes, including aging, DNA repair, and cell cycle progression. Its abnormal activity is linked to diseases such as Parkinson’s disease, cancer, and metabolic disorders, making it a potential target for therapeutic intervention. While small molecule inhibitors have been studied, peptide-based inhibitors offer a promising alternative due to their selectivity and bioavailability. This study explores the effects of converting the naturally occurring cyclic inhibitor peptide of SIRT2 (S2iL5) into a non-cyclic form by replacing a residue with FAK (LYS + CF3CO−). The new peptide sequence, Tyr-His-Thr-Tyr-His-Val-FAK (LYS)-Arg-Arg-Thr-Asn-Tyr-Tyr-Cys, was modeled to confirm its stable conformation. Docking studies and MM/GBSA calculations showed that the non-cyclic peptide had a better binding free energy (−50.66 kcal/mol) compared to the cyclic S2iL5 (−49.44 kcal/mol). Further mutations generated 160,000 unique peptides, screened using a machine learning-based QSAR model. Three promising peptides (Peptide 1: YGGNNVKRRTNYYC, Peptide 2: YMGEWVKRRTNYYC, and Peptide 3: YGGNGVKRRTNYYC) were selected and further modeled. Molecular dynamics (MD) analyses demonstrated that Peptide 1 and Peptide 2 had significant potential as SIRT2 inhibitors, showing moderate stability and some structural flexibility. Their best binding free energies were −59.07 kcal/mol and −46.01 kcal/mol, respectively. The study aimed to enhance peptide flexibility and binding affinity, suggesting that optimized peptide-based inhibitors can interact effectively with SIRT2. However, further experimental validation is necessary to confirm these computational predictions and evaluate the therapeutic potential of the identified peptides.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Hematology Research Unit (HRU), King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Center of Artificial Intelligence for Precision Medicine (CAIPM), King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Histocompatibility and Immunogenetics Laboratory, Prince Abdulmajed Dialysis Center, King Fahd General Hospital, Ministry of Health, Jeddah 21589, Saudi Arabia.
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
ORCID-Profile: Fatmah M A Naemi, Hisham N Alatyb
Förderung
- King Abdulaziz University
- The Deanship of Scientific Research (DSR) at King Abdulaziz University (KAU), Jeddah, Saudi Arabia
Zitieren
APA
Alkhatabi, H. A., Naemi, F. M. A., Alsolami, R., & Alatyb, H. N. (2024). Computational Design and Optimization of Peptide Inhibitors for SIRT2. Pharmaceuticals, 17(9), 1120. https://doi.org/10.3390/ph17091120
Vancouver
Alkhatabi HA, Naemi FMA, Alsolami R, Alatyb HN. Computational Design and Optimization of Peptide Inhibitors for SIRT2. Pharmaceuticals. 2024;17(9):1120. doi:10.3390/ph17091120
BibTeX
@article{Alkhatabi2024,
author = {Alkhatabi, Heba A and Naemi, Fatmah M A and Alsolami, Reem and Alatyb, Hisham N},
title = {Computational Design and Optimization of Peptide Inhibitors for SIRT2},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {9},
pages = {1120},
doi = {10.3390/ph17091120}
}
EUVIMED